Press releases

3 March, 2025

Regulatory

Delisting of the shares of Abliva: last day of trading 17 March 2025

In accordance with Nasdaq Stockholm AB’s decision, following an application from the Board of Directors of Abliva AB (publ), the shares of Abliva will be delisted from Nasdaq Stockholm. The [&he ...

26 February, 2025

Regulatory

Notice of Extraordinary General Meeting in Abliva AB (publ)

At the request of Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., which, following its public offer to the shareholders of Abliva AB (publ) (“Abliva”), holds ...

25 February, 2025

Regulatory

Abliva applies for delisting and will convene an extraordinary general meeting

The outcome of the extended acceptance period in the public offer from Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., regarding Abliva AB (publ) ...

21 February, 2025

Regulatory

Abliva AB Year-End Report January – December 2024

Positive Interim Analysis of the FALCON Study

15 December, 2024

Regulatory

Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming

The Board of Directors unanimously recommends the shareholders to accept the offer.

29 November, 20249 December, 2024

Regulatory

Abliva AB Interim Report January – September 2024

- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -

30 August, 20249 December, 2024

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the ...

22 August, 20249 December, 2024

Regulatory

Abliva AB Interim Report January – June 2024

FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility

19 July, 2024

Regulatory

Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...

18 July, 2024

Regulatory

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...

31 May, 2024

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 103,149,954, as a result of a preferential rights issue announced by the Board of ...

23 May, 2024

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.